Subscribe
shutterstock_685347493_katherine_welles
Katherine Welles / Shutterstock.com
27 August 2020Americas

BMS to acquire Forbius in oncology expansion

Bristol Myers Squibb (BMS) has announced a deal to acquire protein engineering company  Forbius, including its portfolio of protein inhibitors.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
BMS partners with drug accelerator to launch biotech
5 February 2020   Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.
Americas
Bristol-Myers Squibb to acquire Celgene in $74bn deal
3 January 2019   American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.
Generics
Sigmapharm to appeal Pfizer and BMS’ Eliquis win
3 September 2020   Generics maker Sigmapharm Laboratories is appealing against a court win for Pfizer and Bristol Myers Squibb over patents for blood-thinner Eliquis.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
BMS partners with drug accelerator to launch biotech
5 February 2020   Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.
Americas
Bristol-Myers Squibb to acquire Celgene in $74bn deal
3 January 2019   American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.
Generics
Sigmapharm to appeal Pfizer and BMS’ Eliquis win
3 September 2020   Generics maker Sigmapharm Laboratories is appealing against a court win for Pfizer and Bristol Myers Squibb over patents for blood-thinner Eliquis.

More on this story

Americas
BMS partners with drug accelerator to launch biotech
5 February 2020   Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.
Americas
Bristol-Myers Squibb to acquire Celgene in $74bn deal
3 January 2019   American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.
Generics
Sigmapharm to appeal Pfizer and BMS’ Eliquis win
3 September 2020   Generics maker Sigmapharm Laboratories is appealing against a court win for Pfizer and Bristol Myers Squibb over patents for blood-thinner Eliquis.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent